Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine

Jeremy Hobart; Tjalf Ziemssen; Peter Feys; Michael Linnebank; Andrew D. Goodman; Rachel Farrell; Raymond Hupperts; Andrew R. Blight; Veronica Englishby; Manjit McNeill; Ih Chang; Jacob Elkins

doi:10.1007/s40263-018-0586-5

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine

Jeremy Hobart^*
, Tjalf Ziemssen
, Peter Feys
, Michael Linnebank
, Andrew D. Goodman
, Rachel Farrell
, Raymond Hupperts
, Andrew R. Blight
, Veronica Englishby
, Manjit McNeill
, Ih Chang
, Jacob Elkins

^*Corresponding author for this work

Peninsula Medical School

Technische Universität Dresden
Hasselt University
Witten/Herdecke University
University of Rochester
University College London
Zuyderland
Acorda Therapeutics, Inc
Biogen IDEC

Research output: Contribution to journal › Article › peer-review

14 Downloads (Pure)

Original language	English
Pages (from-to)	61-79
Number of pages	0
Journal	CNS Drugs
Volume	33
Issue number	1
DOIs	https://doi.org/10.1007/s40263-018-0586-5
Publication status	Published - Jan 2019

Access to Document

10.1007/s40263-018-0586-5

Hobart ENHANCE primary ms CNS Drugs Resubmission FAM-17923 10-04-2018 jh

Cite this

Hobart, J., Ziemssen, T., Feys, P., Linnebank, M., Goodman, A. D., Farrell, R., Hupperts, R., Blight, A. R., Englishby, V., McNeill, M., Chang, I., & Elkins, J. (2019). Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine. CNS Drugs, 33(1), 61-79. https://doi.org/10.1007/s40263-018-0586-5

@article{7ee0720497c541e09d86d75040ab4ea2,

title = "Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine",

author = "Jeremy Hobart and Tjalf Ziemssen and Peter Feys and Michael Linnebank and Goodman, \{Andrew D.\} and Rachel Farrell and Raymond Hupperts and Blight, \{Andrew R.\} and Veronica Englishby and Manjit McNeill and Ih Chang and Jacob Elkins",

year = "2019",

month = jan,

doi = "10.1007/s40263-018-0586-5",

language = "English",

volume = "33",

pages = "61--79",

journal = "CNS Drugs",

issn = "1172-7047",

publisher = "Adis",

number = "1",

}

Hobart, J, Ziemssen, T, Feys, P, Linnebank, M, Goodman, AD, Farrell, R, Hupperts, R, Blight, AR, Englishby, V, McNeill, M, Chang, I & Elkins, J 2019, 'Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine', CNS Drugs, vol. 33, no. 1, pp. 61-79. https://doi.org/10.1007/s40263-018-0586-5

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine. / Hobart, Jeremy; Ziemssen, Tjalf; Feys, Peter et al.
In: CNS Drugs, Vol. 33, No. 1, 01.2019, p. 61-79.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine

AU - Hobart, Jeremy

AU - Ziemssen, Tjalf

AU - Feys, Peter

AU - Linnebank, Michael

AU - Goodman, Andrew D.

AU - Farrell, Rachel

AU - Hupperts, Raymond

AU - Blight, Andrew R.

AU - Englishby, Veronica

AU - McNeill, Manjit

AU - Chang, Ih

AU - Elkins, Jacob

PY - 2019/1

Y1 - 2019/1

UR - https://pearl.plymouth.ac.uk/pms-research/1056/

U2 - 10.1007/s40263-018-0586-5

DO - 10.1007/s40263-018-0586-5

M3 - Article

SN - 1172-7047

VL - 33

SP - 61

EP - 79

JO - CNS Drugs

JF - CNS Drugs

IS - 1

ER -

Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine

Access to Document

Other files and links

Cite this